Holen Sie sich die Stockscreener-App
10.49
0.38%
-0.04
Vorhandelsmarkt:
10.49
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$10.53
Offen:
$10.44
24-Stunden-Volumen:
9.99M
Relative Volume:
1.07
Marktkapitalisierung:
$12.23B
Einnahmen:
$14.33B
Nettoeinkommen (Verlust:
$-3.79B
KGV:
-3.3091
EPS:
-3.17
Netto-Cashflow:
$1.84B
1W Leistung:
+1.94%
1M Leistung:
+2.94%
6M Leistung:
+21.27%
1J Leistung:
-8.38%
1-Tages-Spanne:
$10.36
$10.61
1-Wochen-Bereich:
$10.22
$10.61
52-Wochen-Spanne:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Vergleichen Sie VTRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
10.49 | 12.16B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.63B | 260.53M | 4.77B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Is now a turning point for Viatris Inc.Analyst Downgrade & Consistent Return Strategy Ideas - newser.com
Can Viatris Inc. (VIA) stock surprise markets with earningsWeekly Investment Recap & Step-by-Step Swing Trade Plans - newser.com
Will Viatris Inc. stock benefit from upcoming earnings reportsJuly 2025 Review & Real-Time Market Sentiment Alerts - newser.com
Viatris Inc. stock outlook for YEARJuly 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com
Viatris declares quarterly dividend of $0.12 per share By Investing.com - Investing.com Nigeria
What is the fair value estimate for Viatris Inc. (VIA) stock in 2025Trade Signal Summary & Daily Oversold Stock Bounce Ideas - newser.com
Viatris (VTRS) Q3 Earnings Report Preview: What To Look For - TradingView
Can volume confirm reversal in Viatris Inc.Portfolio Value Summary & Consistent Income Trade Recommendations - newser.com
Viatris and Locus Biosciences to develop antibacterial therapies for ophthalmic infections - Eyes On Eyecare
Policy Engagement to Break Down Barriers to Access and Build Resilient Health Systems at Viatris - ACCESS Newswire
Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2025 - MarketScreener
Viatris declares quarterly dividend of $0.12 per share - Investing.com
Viatris Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Is it time to cut losses on Viatris Inc.Trade Signal Summary & Low Risk Entry Point Guides - newser.com
Viatris Announces Quarterly Dividend - Yahoo Finance
What’s the recovery path for long term holders of Viatris Inc.July 2025 Final Week & Pattern Based Trade Signal System - newser.com
What does recent volatility data suggest for Viatris Inc.Trend Reversal & Stepwise Swing Trade Plans - newser.com
Is Viatris Inc. (VIA) stock overpriced at current multiples2025 Price Momentum & Smart Money Movement Tracker - newser.com
Is Viatris Inc. stock recession proofTrade Exit Report & Safe Capital Growth Tips - newser.com
Will Viatris Inc. stock recover faster than peersAnalyst Downgrade & Entry and Exit Point Strategies - newser.com
Will Viatris Inc. stock return to pre crisis levelsMarket Performance Recap & Consistent Profit Alerts - newser.com
Viatris to Report Q3 Earnings: Is a Beat in the Cards for the Stock? - Zacks Investment Research
Why Viatris Inc. stock could be next big winner2025 Trading Volume Trends & Safe Entry Zone Tips - newser.com
3 Stocks Under $50 We’re Skeptical Of - The Globe and Mail
Should you wait for a breakout in Viatris Inc.Trade Volume Report & High Return Stock Watch Alerts - newser.com
Will Viatris Inc. stock go up soonPortfolio Risk Report & Safe Swing Trade Setup Alerts - newser.com
Will Viatris Inc. stock reach Wall Street targetsTrade Exit Summary & Community Consensus Trade Signals - newser.com
Viatris marked 25 years of advancing cardiovascular health in Vietnam - VnExpress International
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):